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Abstract.  
 
Hierarchical processes spanning several orders of magnitude of both space and time 
underlie nearly all cancers. Multi-scale statistical, mathematical, and computational 
modeling methods are central to designing, implementing and assessing treatment 
strategies that account for these hierarchies. The basic science underlying these 
modeling efforts is maturing into a new discipline that is close to having its first clinical 
successes. The purpose of this review is to capture the state-of-the-art as well as the 
key barriers to success for multi-scale modeling in clinical oncology. We begin with a 
summary of the long-envisioned promise of multi-scale modeling in clinical oncology, 
including the synthesis of disparate data types into models that reveal underlying 
mechanisms and allow for experimental testing of hypotheses.  We then evaluate the 
mathematical techniques employed most widely and present several examples 
illustrating their application as well as the current gap between pre-clinical and clinical 
applications. We conclude with a discussion of what we view to be the key multi-scale 
modeling challenges and opportunities for multi-scale modeling in clinical oncology. 
 
Key terms. cancer, mathematical modeling, predictive oncology, numerical modeling, 
computational modeling, agent-based modeling, cancer screening, epidemiology 
  
	
4	
	
Introduction 
 
 Cancer involves spatial scales ranging from RNA to gene networks to patients to 
entire populations, and mathematical modeling has provided valuable insights at each 
level. Successes include uncovering the impact of genetic regulatory circuits on spatial 
dynamics at cell and tissue levels1, identifying molecular targets for therapeutic 
interventions2,3, establishing tumor angiogenesis as a therapeutic target4-6, and 
uncovering the potential of cancer immunology7. Cancer also involves diverse temporal 
scales ranging those of gene expression and receptor-ligand interactions (minutes to 
hours) to tumor growth and metastasis (months to years). Multi-scale modeling that 
transforms diagnosis and treatment by bridging these diverse spatio-temporal scales 
has long been pursued, and is now maturing to the point where it shows strong promise 
for solving critical problems in biology in general (REF), and clinical oncology in 
particular.  
 The review begins with overviews of the role that multi-scale modeling can play 
in oncology, before discussing several of the common mathematical techniques used to 
attack those problems.  The overarching goal of these models is to make a prediction 
which can then be tested against experiment (either in silico, in vitro, or in vivo) which 
can lead to model improvement and, eventually, clinical application.  We then examine 
the various areas that are currently barriers to success in applying the methods of multi-
scale modeling to clinical oncology.  The review is designed for members of the cancer 
biology and oncology communities who are interested in learning more about multi-
scale modeling, as well as those in the modeling community who have recently become 
interested in using their tools to study cancer. 
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The role of multi-scale modeling in cancer 
 
Dissecting the multiscale character of cancer to identify therapeutic targets 
 The long-envisioned promise of multi-scale modeling in clinical oncology revolves 
around quantification of the hierarchical disease process and the multi-scale feedback 
structures that enable genetic abnormalities to manifest at the levels of tissues, organs, 
and systems (see Figure 1 for an overview), and Figure 2 for the specific case of 
Barret’s Esophagus where	multi-scale effects of inflammation on the development and 
subsequent behavior of a tumor is described). A goal of multi-scale modeling is to 
identify how perturbations at each level can affect the system as a whole, and then to 
exploit this to attack cancers. The genomic level provides a means of tumor sub-
stratification, which is a first step between identifiers and potential function. Well-known 
genetic mutations can initiate oncogenesis as these genes translate to the scale of 
molecular processes, which in turn translate to cellular behavior. These molecular 
processes can be seen as functional consequences of genetic abnormalities, and 
involve changes in cell signaling, receptor status activation, genetic regulation, cellular 
movement and interactions with the extracellular milieu. A key role of multi-scale 
modeling at this level has been developing knowledge of how “normal” molecular 
control structures function and, by contrast, how genetic abnormalities produce 
dysfunction.  
 At the cellular level, tumors are increasingly recognized as complex, non-clonal 
cell populations with their own internal dynamics arising from multi-scale interactions 
between mutated cells and the normal cells exposed to an abnormal signaling 
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environment. This manifests in inappropriately contextual cell-cell interaction, and is a 
byproduct of and further enhances intra-tumor heterogeneity8: cells housing mutations 
can “hijack” healthy neighbors into propagating a tumor. This in turn fosters selection 
within tumor cell populations, bringing in evolutionary and ecological factors into the 
behavior of cancers, and defines the context by which tumors interact with their 
surrounding host tissue. Multiscale models hold the potential to reveal therapeutic 
targets arising from the ways that cells interact with their neighbors and with their 
physical environment during these processes. 
 At the tissue level, all tumors all start to develop within normal tissue, and 
therefore have access to an “Interaction space” at the border with the host that presents 
a potential area for “hijacking” normal processes and cellular populations. This 
interaction space not only directly affects the growth and selection within the tumor, but 
also selects for tumor processes best able to release cells into the blood stream and 
initiate the process of metastases. The modeling of interactions across the cell, tumor 
and tissue hierarchy therefore holds the potential for unlocking additional therapeutic 
targets. 
 At the system level, the progression of a tumor from a local phenomenon to a 
system-level one represents another key point in the control of cancer, and motivates a 
desire to individualize the representation of tumor characteristics to better determine the 
specific factors involved in a particular tumors progression. Personalized tumor 
modeling might integrate baseline molecular potential arising from identified genetic 
profiling of the primary tumor cells or tumor stem cells with the set of possible 
behavioral trajectories possible in a multi-cellular tumor that is actively interacting with 
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its host. These latter characteristics might be represented by tumor-level properties 
determined by different modalities, such as histology or imaging, which would provide 
calibration targets for the lower-level mechanisms incorporated into such a model, and 
then be used to project multiple possible outcomes based on other personal factors, 
such as health status or interventions.  
Finally, at the patient population level, the ability to potentially “simulate” an 
individual tumor provides a pathway to the generation of simulated populations of 
cancer patients. These simulated populations, which would provide a more 
sophisticated accounting for mechanisms than traditional population modeling, would be 
key to represent and account for the fact of the “rarity” of cancer events, thereby 
accounting for stochastic processes involved in mutational events, allow the generation 
of finer grained data sets for identification of more subtle patterns in the pre-cancerous 
and early stage conditions. Ultimately, these models would form the basis of in silico 
clinical trials for potential therapeutic regimens, and provide another potential pathway 
for the design and development of cancer therapeutics. 
 
Characterizing drug targets 
Molecular targets that are cancer drivers are ultimately part of a mechanistic 
cascade9. Antitumor effects can be caused by many pharmacological interventions, 
both direct (e.g., kinase inhibition10) or indirect (e.g., immune-mediated therapy11). 
Given the broad landscape of potential pharmacological agents, modeling and 
simulation has a fundamental role in facilitating the investigation of potential targets. 
Systems pharmacology12 is an emerging and powerful approach tool in the quantitative 
modeler’s toolbox for guiding the early stages of discovery13, especially when tool 
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compounds are unavailable and information is sparse about target properties such as 
abundance in target tissues and turnover14. Pharmacokinetic-pharmacodynamic (PK-
PD) models incorporate compartmental15, or physiologically-based16, models of drug 
distribution and empirical or semi-mechanistic models of drug action17. They are most 
suited for investigating the effects of drugs on molecular targets when tool molecules 
are available to probe disease pathways. At the other end of the scale, 
pharmacometric18 models, which incorporate statistical and mechanistic features of the 
patient population being studied, can be used to quantify the effects of a particular 
treatment on populations. The statistical technique of mixed effects modeling can be 
applied to find explanatory variables (covariates) or PK, PD and eventually, as in cancer 
trials, clinically significant endpoints such as overall or progression-free survival19. All 
these modeling approaches ultimately characterize drug targets across the spectrum20 
of target qualification (cell and tissue), pharmacology (nonclinical models and humans) 
and disease effect (populations).  
Adverse side-effects and lack of efficacy are the two major sources of attrition in 
drug design field (REF). Substantial efforts have been devoted to tackling this 
challenge, among which the systems biology approaches have been playing 
increasingly important roles in addressing the lack of efficacy and undesired off-targets 
effects (REFS). Recent advances in structural bioinformatics have enabled the reliable 
prediction of drug off-target binding sites across the proteome (REF). Large-scale 
network models have also been widely applied to predict the functional effects of 
various therapeutics (REF). And these two approaches have been integrated to provide 
a framework for assessing drug responses in silico (REF). A recent effort incorporated 
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the signaling pathway information for the evaluation of side effects on primary human 
hepatocytes, and obtained insightful results with clinical benefits (REF). Collectively, the 
traditional experiment-based screening strategy to reduce drug off-target effects is 
becoming time- and cost-consuming, while a variety of recently developed 
computational models have begun to make significant contributions to the rational drug 
design. In addition, many computational tools established on ordinary differential 
equations (ODEs) systems have been widely used to model and predict the effects of 
therapeutics on intracellular signaling pathways (REFS). These model tools were 
developed based on protein-protein interaction networks with applications on exploring 
optimal therapeutic strategies. Collectively, the ODE models with perturbations can be 
used to explore in silico candidate condition, screen out critical factors, and guide 
biological experiments, by investigating the drug combination effects with well-known 
evaluation indexes such as Loewe additivity (REF) and Bliss independence (REF). 
Finally, using agent-based modeling techniques which integrating multiple biological 
scales together especially including intracellular signaling pathways, multi-scale 
modeling frame plays a crucial role in developing optimal drug therapies in cancer 
research (REF).   
 
Computing the design of anticancer drugs  
 
It is increasingly clear that there must be an extension from the “rational 
discovery” of potential drug candidates, often based on molecular-level assumptions of 
effect, to a “rationale design” process, that moves beyond target identification towards 
characterizing the larger scale consequences of interfering with a particular target gene. 
This necessarily incorporates recognition of the multi-scale nature of cancer, where 
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there are higher-order properties that involve accounting for the behavior of multi-
cellular populations within a tumor, as well as the interactions of that tumor with its host 
environment. Given this understanding, it is critical to account for compensatory 
processes that remain in either the tumor or adjacent host tissue in any attempt to 
understand the potential downstream consequences of a molecular level intervention 
(as is the case with many anti-cancer drugs). Quantitative models that can contextualize 
the multi-scale processes involving the development and behavior of cancer have an 
important role to play in this line of investigation21. 
 
Digital screening of anticancer drugs 
 
 Traditional drug discovery replies upon either rational design or high-throughput 
screening using a library that contains millions of compounds selected for and then 
screened for efficacy against a target of interest. While this approach has been 
successfully used to discover many effective anticancer drugs, it can be enhanced 
through digital drug screening, a powerful drug discovery technology in the post 
genome era. In addition to advances in chemoinformatics22 and the deciphering of the 
human genome sequence there has been an enormous increase in the types of 
chemical compounds, biological and physiological systems, and diseases that have 
been digitized, stored and archived in publically accessible databases, such as 
PubChem, ChemSpider and ChEBI23. These databases offer a platform for releasing 
and publishing experimental data on chemical compounds and their associated 
structure and functional data. They also offer user-driven search engines that allow 
users to define and search a particular or class of chemical compounds.  
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 Conversely, while large sets of biological and medical data are frequently 
generated, the validation and further standardization of these data remains significant 
challenge. One of the difficulties is the poor reproducibility and reliability of these 
biological and clinical data due to complexity of biological systems and hard-to-access 
human samples. The development of bioartificial tissue and organ-on-a-chip24 system 
could help accumulate more clinically-relevant biological and physiological data for 
digital anticancer drug screening. The digitalization of cancer diagnoses offers another 
opportunity to deposit and publish clinical and oncological data through internet. Some 
of these databases (e.g., Therapeutic Targets Darabase and PharmGKB) are available 
today for drug screening.  
 Another critical element of digital drug screening is the computational models that 
bridge the data to a cancer target. Such models must be multi-scale and target-driven 
due to the multiple spatial and temporal scales at which the motivating biological and 
clinical data are collected. Algorithms also need to be developed to predict whether 
compounds or biological agents including proteins or peptides can be translated into 
anticancer drugs. For example, BioMap® (human primary cell phenotypic profiling 
services developed by DiscoveRx Co.) consists of primary human cell-based assay 
systems, a database of reference compound profiles, and computational data mining 
and analysis tools. This computational model will allow users to virtually correlate a 
compound’s activity to clinical outcomes. A ChemScore system that uses reactivity 
based fingerprints of compounds as filters has been developed to determine a reactant-
like and a product-like score for virtual drug screening25.  
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 Taken together, the combination of available databases and computational 
models, offers unprecedented opportunities to build computational models for drug 
screening, thereby enabling a fundamental shift from traditional high-throughput 
screening to data-driven screening of potential anticancer drugs.  
 
Optimizing dosage, drug combinatorics, scheduling, and safety  
 
 A critical challenge in the development of anti-cancer drugs is the optimization of 
the dosing strategy including the proper dosing, timing, and scheduling of drug 
administration (REF). Optimally selecting treatments for a particular cancer subtype, 
particularly treatments that involve combination therapy, is an extraordinary challenge 
for the number of potentially relevant adjustable parameters is too large to adequately 
investigate in clinical trials. Thus, to accelerate progress on this fundamental problem, a 
robust and practical theoretical-experimental approach is required. Having an 
accurate—and clinically useful—multi-scale modeling approach can reduce the number 
of experiments that must be performed by dramatically reducing the space that must be 
searched to test a given hypothesis. 
The classical “maximal tolerated dose” (MTD) approach currently used in early 
Phase 1 clinical trials of anticancer drugs (REF) can be irrelevant in many situations. 
For example, some compounds simply do not present a toxicity profile such as reaching 
the MTD in a dose finding phase. For other compounds with a well-identified MTD, the 
upper-limit dose may not be appropriate when the compound is given in combination 
with other therapeutics—which is commonly the case (REF). Efficacy and toxicity are 
central issues in design of patient-specific chemotherapy regimens, but do not lend 
themselves well to trial-and-error approaches. A broad range of coupled in vitro and 
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numerical modeling techniques are becoming available that offer much promise for 
rapid efficacy and toxicity screening.  
Cellular and tumor-level responses may be deduced from the responses of 
bioartifical tissues, organ-on-a-chip systems, in vitro tumor models, and murine systems 
in typical screening procedures. These systems also show promise for assessing 
toxicity of drug regimens. A particularly promising avenue is screening of compounds on 
bioartificial tissues whose cells derive from a patient’s own induced pluripotent stem 
cells26.  
Computer models could play a pivotal role in determining efficacy, regimen and 
safety of drug combinations. Multi-scale modeling can anticipate potential synergies 
between compounds’ mechanisms of action, thus providing a rational method for 
selecting a dose that would improve efficacy without affecting safety. Progress has 
already been made using bioinformatics algorithms27; however, applications of multi-
scale modeling to solving this very important clinical problem remain to be fully 
explored.  
 
Assessing intervention, prevention, and cancer screening strategies  
 
 Multi-scale frameworks that explicitly model clinical outcomes in terms of 
underlying biological processes in conjunction with the physical and physiological 
characteristics of the instrumentation used for screening or drug delivery are likely to 
suggest improvements that cannot be gleaned from traditional natural history models of 
cancer development and drug response. Such traditional models typically ignore 
important biological processes and time scales in the formation of cancer and its 
precursors. In contrast, multi-scale models are poised to provide a more comprehensive 
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understanding of the underlying mechanistic processes as well as the spatio-temporal 
characteristics of cancer screening and surveillance protocols (e.g., using high-
resolution imaging, biopsies, brushings (collecting cells from the epithelial surface using 
a cytosponge), blood tests). An illustrative example of this reasoning is presented in 
Figure 328. Although regular biopsy-based surveillance is the recommended standard of 
clinical care for most Barrett’s Esophagus (BE) patients who have not progressed to 
dysplasia or cancer, it is not clear whether screening under current guidelines is 
clinically optimal and cost-effective. Curtius et al. describe a computational cell-level 
mutliscale model for the neoplastic progression of Barrett's metaplasia to esophageal 
adenocarcinoma allowing for variation in segment length, presence of dysplastic cells in 
the crypt-structured epithelium and their potential detection by biopsy28.  Thus, multi-
scale-based screening models can potentially be used to better understand the clinical 
performance (sensitivity/specificity) of various screening methods and the sources that 
limit their clinical utility. 
 
 
State-of-the-art multi-scale approaches to cancer 
 
Multi-scale Network signaling models 
 
 Advances in mechanistic modeling of signaling networks present opportunities 
for better understanding of therapeutic targets, designing therapeutic regimen including 
combination therapies, as well as the de novo design of drugs. Models of growth factor 
signaling networks, such as vascular endothelial growth factor (VEGF) and epidermal 
growth factor (EGF), have been particularly well developed. The VEGF models describe 
molecular-detailed kinetic interactions between different splice isoforms of VEGF and 
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their cognate receptors VEGFR1 and VEGFR2 and co-receptors neuropilins-1 (NRP1) 
and NRP2; the models comprise three compartments: blood, normal and tumor and 
they also take into account VEGF binding to the extracellular matrix, and soluble factors 
such as soluble VEGFR129,30. Molecular-detailed intracellular signaling models that 
include receptor dimerization, internalization, recycling, and degradation can potentially 
be used for simulating intracellular drug targeting with, for example tyrosine kinase 
inhibitors31. The kinetic receptor-ligand interaction model has been extended to describe 
PK/PD of VEGF-neutralizing anti-angiogenic drugs including the antibody 
bevacizumab30, and aflibercept29, a fusion of specific domains of VEGFR1 and 
VEGFR2. They were compared with extensive available clinical data. The difference 
between these molecular-detailed PK/PD models and more conventional models is in 
the mechanistic level of detail with which the molecular interactions are represented. 
Therefore, the model predicts the amounts not only of the drug in the compartments, but 
also the detailed distribution of the different ligands (e.g., those bound to the cell-
surface receptors, extracellular matrix, and free in the interstitium)32. For the EGF 
system a molecular-detailed approach has been used to design and optimize an 
antibody for cancer applications33.  
 
Pharmacometrics 
 
 A popular definition of pharmacometrics is “the science of developing and 
applying mathematical and statistical methods to: a) characterize, understand, and 
predict a drug's pharmacokinetic and pharmacodynamic behavior, b) quantify 
uncertainty of information about that behavior, and c) rationalize data-driven decision 
making in the drug development process and pharmacotherapy”34. In practice, 
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pharmacometrics employs nonlinear mixed effects modeling techniques35 that combine 
structural models (algebraic or differential equations) that are nonlinear in their 
parameters with nested variability in the clinical observations (i.e., variation among and 
within patients) and trial execution components (i.e., patient adherence and dropout 
rate). There have been many applications of nonlinear mixed effects models to clinical 
PK-PD, also in oncology36,37. What has made its impact possible is the early availability 
of computer software38 and frequent application to situations where other techniques 
would have been difficult to deploy, such as clinical studies where the number of 
patients is large, but the measurement and sampling schedule is sparse. Since this 
class of models is informed by data, mechanistic detail is a function of available 
information. However useful, nonlinear mixed effects are not the only tool that can be 
used to understand dose-exposure-response relationships in vivo. It is through the 
combination and use of multiple, “fit for purpose” modeling approaches, depending on 
the appropriate biological scale, that we can hope to understand cancer etiology and 
pharmacotherapy39. 
 
Partial differential equations 
 
 For handling clinical data that have spatial dimensions as independent variables 
(i.e., data that do not depend solely on time), mathematical models based on partial 
derivative equations (PDEs) may be more appropriate than those based on ordinary 
differential equations (ODEs) which are more amenable to the applications described in 
the previous two sections. For example, medical images which are composed of 
rectangular, spatially-resolved voxels describing the shape, location, and texture of the 
tumor in addition to underlying physiological processes40, cannot be readily handled by 
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ODE models. More generally PDE models could be useful when the available data is 
multidimensional41. Most spatial models describe the movement of cancer cells through 
reaction-diffusion42 or advection43 terms. The applications are numerous, ranging from 
monitoring the evolution of slowly evolving tumors such as lung metastases44 to defining 
surgery or irradiation margins45,46, improving the insight offered by images47. (See 
Figure 4). PDE models have also been used to evaluate the spatio-temporal distribution 
of metastases over time48, as well as mutations and resistance to treatment49. However, 
most applications require being able to recover the parameters of the model from 
clinical data in order to perform patient-specific simulations or predict patient-specific 
outcome. 
 It is important to note that PDE models are (relatively) computationally expensive 
to solve. Even if they can take more from available data (e.g., every voxel value of an 
image could be used for calibrating) this makes data assimilation challenging. Classical 
optimization techniques can often be too expensive to be realistically used. More 
advanced techniques relying on reduced-order models50 or exploiting the features of the 
solution to a model51, may prove more successful for assimilating clinical data. 
 
Spatially discrete/cellular agent models 
 
 One class of computational modeling that has recently increased in popularity is 
the representation of biological structures with spatially discrete, cell-as-agent models. 
Methods that fall into this category are agent-based models (ABMs), individual based 
models (IBMs), cellular automata, and cellular Potts Models. For simplicity’s sake, these 
methods will be globally described as agent-based modeling, and can be generally 
described as discrete event, object oriented, rule based, and often spatially explicit 
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methods for dynamic computer modeling that represent systems as a series of 
interacting components52. ABMs are computer programs that generate populations of 
discrete computational objects (or agents) that correspond to the component-level at 
which the reference system is being examined. These computational agents are 
organized into agent classes representing groupings of agents of a similar type defined 
by shared properties and characteristics. Agents are governed by agent rules, which are 
a series of instructions that allow the agent to be treated as an input-output object. 
Individual agents incorporate the properties and rule-structures of their parent agent 
class, but are able to manifest diverging behavioral paths based on the differing local 
inputs, generating population/system level outputs from the heterogeneous behavioral 
trajectories of individual agent instances that embody lower-level knowledge and 
mechanisms. ABMs intrinsically cross scales of biological organization, utilizing 
behavioral rules (scale 1) to determine individual agent behavior (scale 2), and then 
aggregating individuals into population dynamics of the global system (scale 3).  When 
applied to biological systems, cells form a natural agent level within this organizational 
structure. Subcellular components (e.g., genes, enzymes, receptors, and structural 
elements) are represented as state variables for the cellular agents. Their behavior and 
interactions (e.g., gene transcription, intracellular signaling, protein synthesis) for the 
rules for the cellular agents, and can be represented by a wide range of mathematical 
and computational formulations including (for example) ordinary, partial or stochastic 
differential equations, discrete event processes, conditional statements, and Boolean 
algebra. Individual cellular agents interact with each other by manipulating state 
variables of their neighbors or their shared environment, resulting in cell-population 
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dynamics. Figure 5 depicts an ontological description of an agent-based model, with an 
emphasis on its generality that can be tailored to specific modeling tasks. Given these 
framework, ABMs have been extensively used to study tumor growth and behavior (see 
ref. (1)-(3)) for a recent reviews of the use of ABM to study cancer). 
Multi-scale, agent based modeling has been used to generate high-fidelity 
replications of tumor structure. The natural spatial representation of ABMs allows them 
to generate “realistic” tumor structures incorporating multiple cell types and capturing 
the heterogeneity increasingly recognized as a part of cancers53. This permits a more 
detailed investigation of the multi-scale consequences of genetic or molecular 
perturbations, and offers the promise of potentially personalizing models based on 
histological features54. 
ABMs also allow examination of fundamental processes involved in oncogenesis 
by facilitating a parsimonious approach that provides insight into fundamental processes 
involved in tumor growth and development55. ABMs can also provide linkages to the role 
of general biological processes, like inflammation, in the development and progression 
of cancer60. 
Finally, ABMs can bridge cancer mechanism to simulated populations. The 
intrinsic stochasticity seen in ABMs allows them to be used to generate simulated, in 
silico populations of virtual patients. This is a critical capability, particularly in cancer, 
where the development and progression of tumors can span years and decades. ABMs 
of this type can be used to add increased mechanistic detail to traditional population-
level, epidemiological models, thus far used to explore more basic processes in 
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oncogenesis56, but also providing a potential means of performing in silico clinical trials 
for both preventative and therapeutic modalities. 
 As with all modeling methods, agent-based modeling is not without its limitations. 
Most of these stem from the fact that ABMs do not have a common formal description, 
which limits the ability to subject them to formal analysis. Their “similarity” to biological 
systems, particularly in terms of the heterogeneity and non-linearities in their behavior, 
makes formal, comprehensive exploration of their parameter space difficult and 
essentially only able to be accomplished using very large sets of simulations. Added to 
this is the fact that ABMs are relatively computationally expensive and difficult to 
distribute across modern, distributed computing architectures, with the result that very 
often biomedical ABMs are treated more akin to experimental objects where their use is 
dependent upon finding some subset of parameters that can provide “realistic” behavior. 
Despite this limitation, however, ABMs can serve a very useful purpose as transitioning 
models that can serve as bridges between biological objects/knowledge and more 
formal mathematical representations. 
 
Branching processes 
 
 Disruption of normal cell proliferation and differentiation is the sine qua non of the  
malignant state. However, numerous experimental and clinical studies provide evidence 
that the proliferation and differentiation kinetics in normal and premalignant cells are 
also of critical importance in the carcinogenic process. This notion was further enforced 
by analytic findings from mathematical modeling of cancer incidence patterns57. A 
prototype branching process model of cancer is the two-stage clonal expansion (TSCE) 
model58. Initially, this model was formulated with stochastic clonal expansions of both 
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normal and intermediate (or premalignant) stem cells. However, due to the typically very 
large (and highly regulated) size of the normal tissue stem cell pool, the version most 
frequently used assumes a deterministic number of normal tissue stem cells. The basic 
TSCE model is characterized by two rate-limiting events in normal tissue stem cells 
(premalignant tumor initiation and malignant transformation) together with a stochastic 
growth process of premalignant cells that can undergo malignant transformation. 
Various extensions of this model have been put forward (multistage clonal expansion 
(MSCE) models) to better explain cancer incidence patterns in registries and cohort 
studies59. The availability of analytical tools and likelihood expressions for population-
level clinical observations (e.g., cancer incidence, prevalence of a precursor such as 
colonic adenoma or dysplasia in Barrett’s esophagus patients) greatly facilitates 
likelihood-based parameter estimation via gradient methods or Markov-Chain Monte 
Carlo (MCMC) techniques. The ‘mathematical bridge’ that connects the cellular-level 
with the tissue-level is a filtered Poisson process. The tissue-level is further connected 
to the population level observation (cancer occurrence) through the model hazard 
function. 
 
Homogenization approaches  
 Linear homogenization approaches comprise the simplest techniques for 
estimating parameters describing cell health and function from measurements 
conducted on a tissue construct. From the perspective of screening for safety, the 
desired outcomes are parameters describing electrophysiological and mechanical 
functioning of individual cells. From the perspective of screening for efficacy, cancer 
culture models such as the Xu model60 exist, and the challenge is determining how 
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chemotherapy agents affect the tumor periphery and factors promoting malignancy. 
Models estimating tissue and cellular mechanics from multiple loadings of tumor models 
are capable of estimating these changes61, and for estimating effects on cells, protein 
structures, and networks62. Although techniques are preclinical at present, the capacity 
to test chemotherapy regimens on both heart tissue equivalents from a patient’s own 
transdifferentiated cells and tumor equivalents from a patient’s own tumor cells shows 
much promise. Ongoing challenges relate to refinement of electrophysiological and 
mechanical models to account for local variations within tissues, and to include 
nonlinear phenomena. 
 
Hybrid models 
 
 Multi-scale hybrid models combine different modeling methodologies; e.g., 
intracellular signaling described by ODEs combined with 3D distributions of oxygen, 
growth factors and cells described by PDEs, or oxygen and growth factor distributions 
described by PDEs combined with discrete cell dynamics represented by agent-based 
modeling. In principle, hybrid models could include all types of models. The advantage 
of hybrid modeling is that different parts of the system can be described using the 
methodologies most appropriate for the biological question to be answered, and with a 
spatial and temporal resolution that makes the problem tractable.  
 
 
Barriers to and opportunities for progress  
 
Technical/methodological issues  
 Mathematical complexity 
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There is a tradeoff between mathematical and computational complexity in 
modeling oncological problems, especially when the problem involves a large number of 
interacting components (cell-types), non-linear signaling between components 
(feedback loops), and stochastic behavior (noise). The main challenge in developing 
useful multi-scale models is therefore the choice of mathematical abstraction 
(continuum, discrete, lattice) and choice of relevant (rate-limiting) processes, which may 
operate at different time and length scales. However, these scales may not be known a 
priori and the appropriate choice may require preliminary studies and/or additional bio-
mechanistic information. A case in point is the problem of emerging resistance to 
chemotherapy in heterogeneous tumors, whether or not the ‘resistance conferring’ 
alterations are preexisting, a result of the tumor and its microenviroment being under 
selection pressure caused by the drug, or simply due to the hypermutability or genomic 
instability of the tumor. Each of these causes requires a distinct mathematical 
description. For example, the size fluctuations of preexisting mutants may well be 
captured by a Luria-Delbrück type of distribution, which allows for mutational jackpots, 
while a drug-induced response is unlikely to do so given the much shorter time scale of 
treatment (REFS). 
Mathematical complexity in oncologic applications of multi-scale modeling arises 
primarily in the formulation of the dynamics of bulk behavior and description of 
underlying constituent processes in the forms described above. It is important to note 
that only in exceptional cases (and often only with many simplifying assumptions) are 
closed form solutions available and parameter identifiability issues limited. Further 
adding to the mathematical complexity is the stochastic nature of many cell-level and 
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sub-cellular processes requiring the proper formulation and solution of discrete or 
continuous-time Markov processes, which capture important fluctuations in the data with 
time. Although the implementation and mathematical treatment of the stochastic 
process may be complex, a considerable advantage is that it lends itself to likelihood-
based methods for parameter estimation and hypothesis testing.  
  
 Lack of necessary data available from standard clinical studies 
  
 It is important to acknowledge that while the multi-scale cancer modeling 
community is rich in models from the nanoscale to the macroscale, we are quite poor in 
data. This a fundamental, if not the fundamental, challenge facing the validation and 
clinical application of multi-scale modeling (REFS). This is particularly true for cases in 
which electrophysiological, transport, and mechanical factors of cells and a pericellular 
region are of interest. For the case of the screening of chemotherapy agents, the key 
difficulties are measuring in the mesoscale range, characterizing the pericellular region, 
and sampling a sufficient number of cells to overcome the high cell-to-cell variability so 
inherent to three dimensional culture. These challenges results in modeling approaches 
that require many (often heuristic) assumptions on model parameters. Consequently, 
application of such models to make clinically relevant predictions is quite limited (REF). 
More directly, the field of multi-scale modeling in cancer has largely been developed 
independent of the data types that are typically available in the clinical setting. The 
community needs to acknowledge that it is not simply enough to test a myriad of 
modeling approaches in silico by systematically varying parameters, coupling constants, 
etc. Rather, to be of clinical utility, the community needs to build multi-scale models that 
can be initialized and constrained with patient specific data that is readily available in 
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the clinical setting (REF). Only by proceeding along this route will we be able to test 
hypotheses about patients that directly testable. One area that is underexplored in 
making progress is the utility of medical imaging data (REFS).  
 The medical imaging technologies of magnetic resonance imaging, x-ray 
computed tomography, positron emission tomography, single-photon emission 
computed tomography, and ultrasound can quantify, at multiple time points and in 3D, 
tumor characteristics at the physiological, cellular, and molecular levels63. Furthermore, 
the images themselves present a natural gridding (i.e., the image pixel or voxel) that 
enables direct application of finite difference and finite element methods. While using 
such data in statistical and informatics driven approaches has launched the fields of 
radioomics and radiogenomics64, such data are only beginning to be incorporated into 
mechanism-based, predictive models of tumor initiation, growth, invasion, and response 
to treatment45,65.	
 
 Limited rigorous assessment of clinical problems  
  
 Another barrier—and opportunity for progress—is that there is frequently a 
limited, or absent, rigorous assessment of the clinical problem from the available 
literature. This plays an equally important as modeling approaches in the success of 
multi-scale modeling in clinical oncology. As has been described66 if a mathematical 
model is likened to a building, assumptions are the ground beneath, and if the 
underlying soil is swamp, the edifice—the model and its resulting inferences—is 
doomed to failure. Therefore, to remove an important barrier towards the success of 
multi-scale modeling in clinical oncology, the community must substantially reduce 
conflicts between model assumptions and clinical problem by rigorous assessments of 
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the clinical literature. As an illustrative example, if the development of a tumor subtype 
is particularly linked to immune response or neoavascularization, but is not incorporated 
into the model system as a basic model assumption, then projected spatiotemporal 
evolution of the tumor fail to capture significant portions of tumor biology. Thus, it is of 
critical important to have a rigorous, biological understanding of the tumor type under 
investigation when designing a multi-scale model. Unfortunately, limited tissue data are 
available for designing multi-scale modeling approaches67.  
 
 Mathematical models of tissue health and function 
 There is a pressing need for multi-scale modeling techniques that enable the use 
of in vitro tissue surrogates and organ-on-a-chip models for safety and efficacy 
screening of chemotherapy agents. Although well-established methods exist for 
applying integrated multi-scale modeling and experiment to assess subtle, drug-induced 
changes to the health and function of cells within simple bioartificial tissue constructs68, 
advances are required to account for such tissues and organ-on-a-chip systems with 
heterogeneous cell populations. With these models in place, the potential to, for 
example, test a regimen of chemotherapy agents on bioartifical tissues mimicking a 
patient’s own tissues will become possible, enabling rapid optimization for both efficacy 
against a patient’s malignant cells and for tolerance by a patient’s healthy cells through 
quantitative evaluation of changes to cell function. 
 
 
Scientific “social” issues 
 
 Intrinsic to any trans-disciplinary endeavor is the need to reconcile different ways 
of viewing the world, and the terms that are used to reflect those views. This is 
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particularly notable in the attempt to link biology with the physical 
sciences/engineering/mathematical fields. Of course it is recognized that biology, as it 
currently stands, is too “complex” for the identification of abstractions that can 
approximate “natural laws.” However, it has been proposed that, until sufficiently 
powerful mathematics is discovered, dynamic computational models representing sets 
of mechanistic hypotheses can stand in for formal mathematical theories for a defined 
context and for a constrained use69. Within this context the importance of specific 
methods is lessened: sufficiently strong hypothesis structures should perform equally 
well when instantiated in a multiplicity of modeling methods; this is the principle of cross 
platform validation. Of course, the quality of the implementation is crucial to establishing 
the trustworthiness of a particular computational model, and there needs to be 
accounting for the relative strengths, weaknesses, and representational capabilities of 
the different methods. There also needs to be some means by which the appropriate 
use-context of a particular model is explicitly defined and determined, in order to avoid 
the misapplication and misinterpretation of a particular model. These issues are 
common to the general use of models and simulations, and have been pragmatically 
addressed through the establishment of guidelines and standards for model credibility, 
testing, and reporting in a domain specific fashion. As with many aspects of 
computational modeling in biomedicine, this process is in its infancy. However, there are 
several initiatives (e.g., the Committee on Credible Practice in Modeling and Simulation 
in Healthcare70) that have started the process by which biomedical models can be 
categorized by their use and purpose. This initiative is of particular importance as the 
field recognizes its eventual goal of using model-aided design and testing in the 
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regulatory arena (for testing of drugs and devices) and for personalized/precision 
decision support. 
 
Conclusion 
 
 No shortage of powerful—and promising—computational techniques exists for 
use in the multi-scale modeling of cancer and cancer treatments. What is lacking, 
however, is access to relevant clinical data and practical modeling approaches to 
incorporating such data into relevant models.  This will allow modelers, 
experimentalists, and oncologists to effectively close the “build model -test-refine cycle” 
by directly testing the predictive power of a particular model and then improving upon it 
to the point where it can, ultimately, be applied to clinical problems.  We also need a 
more rigorous understanding of the key components that go into the growth and 
response to treatment of individual tumor subtypes. Both of these issues are 
exacerbated by the social constructs in academia. In practice, future progress in 
clinically relevant multi-scale modeling in oncology requires interdisciplinary 
collaborations between clinicians, experimentalists (biologists, physiologists, 
biophysicists, bioengineers, etc.), and mathematical and computational modelers. 
Although this truth is clearly recognized at the level of the funding agencies, the difficulty 
in developing such collaborations is generally underappreciated. However, a corollary of 
successfully working across multiple disciplines is the education and training of the next 
generation of students and postdocs who are accomplished at both the bench and 
computer thereby allowing them to explore and integrate their data into clinically useful 
models. Fortunately, this is happening as we speak and therefore the future utility of 
multi-scale modeling in clinical oncology is bright. 
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Figure legends 
 
Figure 1. The continuum of multi-scale components of cancer pharmacological therapy, 
and the role of each of the modeling techniques described in the text. The process 
starts with discovery and characterization of a target, followed by drug lead optimization 
and extensive in vitro and pre-clinical testing. A new medicine will also require 
successful testing in the clinical setting. Public domain image credits (bottom to top): 
NCI Center for Cancer Research (Luana Scheffer, Stephen Lockett, Jairaj Acharya); 
Wikimedia Commons; NCI Center for Cancer Research (Thomas Ried); National 
Cancer Institute (Leidos Biomedical Research, Inc.); National Cancer Institute (Rhoda 
Baer); photo courtesy photos-public-domain.com. 
 
 
Figure 2. Proposed Generative Hierarchies for Cancer and the Effect of Inflammation. A 
depiction of an example of the multi-scale effects of inflammation on the development 
and subsequent behavior of a tumor, incorporating evolutionary and selection effects 
across the scales from DNA to cellular populations. This paradigm posits that increased 
and accumulating genetic damage in an inflammatory milieu leads to a progressive loss 
of the cellular and molecular control structures that govern stable multi-cellular 
organization. The loss of these control structures in the tumor leads a more “colony-like” 
behavior, where the genetic plasticity of the increasingly disordered tumor cells provides 
a potential selection benefit when subjected to therapeutic interventions. The 
incorporation of these concepts into a multi-scale computational model allows the 
exploration of various fundamental processes and behaviors involved in this hypothesis. 
Reprinted with permission from ref. 56. 
 
 
Figure 3. The Multi-scale nature of screening in Barrett’s esophagus (BE). The 
standard screening protocol for BE involves scales from stem cells in the crypt (left) to 
the BE cylindrical segment of the esophagus depicted (right) with rectangles 
representing biopsy samples taken during endoscopy. The BE segment may have 
dysplasia and/or malignant tissue patches that may be missed. During histological 
preparation, portions of each biopsy are sliced by microtome and placed on slides for 
pathologic assessment. A diagnosis is made by microscopic interpretation of crypt and 
cellular architecture, reflecting the most severe tissue grade found from all slides.  
Given the multi-scale nature of the problem, it is natural that a multi-scale-based 
screening model would have great clinical utility. (EAC = Esophageal Adenocarcinoma; 
HGD = High Grade Dysplsia.) 
 
 
Figure 4. This illustrative example uses serial diffusion weighted magnetic resonance 
imaging data to estimate tumor cellularity before and after the first cycle of neoadjuvant 
therapy. The top row indicates the apparent diffusion coefficient (ADC) obtained from 
diffusion weighted MRI data at three time points during therapy.  Given the known 
relationship between ADC values and cellularity, this data is then converted to tumor 
cell number (middle row). The cell number data from the initial and post one cycle time 
points are then fit to a biomechanical model of tumor growth to estimate patient-specific 
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parameters of tumor cell proliferation and migration.  The model, calibrated with the 
patient-specific parameters determined from the fitting procedure, is then run forward in 
time to predict residual tumor burden at the conclusion of neoadjuvant therapy. Model 
predicted cell number can be compared to cell number imaging observations at the final 
time point in order to assess predictive performance.  Details are presented in ref. X. 
 
 
Figure 5. A schematic of an Agent-based modeling format (ABM). The structure of an 
ABM intrinsically incorporates at least three representational scales of the system being 
modeled. For most biomedical ABMs, cells are used for the middle level representation 
(the agent level). Figure reprinted with permission from Elsevier Ltd. 
 
 
Figure 6. Patient-specific drug and cardiotoxicity systems are available, but require 
integrated multi-scale modeling and experiment to apply. Tumor cells can be multiplied 
in systems like the Xu system (REF) for patient-specific drug screening. Commercial 
systems exist for testing patient-specific cardiotoxicity on tissue constructs derived from 
induced pluripotent stem cells (iPSCs); for example. Multi-scale models are required to 
derive metrics of cellular health from measurements of the mechanical function of tissue 
constructs, and for scaling dosages. Image credits: Top center and top right: ref. 71; 
bottom left and bottom center: Invivosciences, LLC. All images used with permission. 
 
